Xequel Bio Announces Positive Results from Phase 1b Study of iNexin™, a Novel aCT1 Ophthalmic Solution
Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance...
Pharmaceutical
MDbio Start Clinical Trials for Pharmaceutical-Grade Products That Target Sleeplessness, Anxiety and Pain; Expected Retail From 2023
Los Angeles, CA, July 14, 2022 (GLOBE NEWSWIRE) -- MDbio are a leading plant-based, wellness solution who provide safe, pharmaceutical-grade...
Allied Corp Successfully Ships Second Commercial Cannabis Flower Export From Colombia to International Market
KELOWNA, British Columbia, July 14, 2022 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to...
New two-year data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration
In the TENAYA and LUCERNE studies, more than 60% of Vabysmo patients could be treated every four months at two...
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets
Strengthens balance sheet with non-dilutive capital at an attractive cost Competitive process results in the sale of 30% of the...
GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the...
Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company
Four new members enhance independence and diversity of Board of DirectorsAlvotech is dual listed on NASDAQ in the U.S. and...
Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company
Four new members enhance independence and diversity of Board of DirectorsAlvotech (NASDAQ and First North Growth Market: ALVO), a global...
TFF Pharmaceuticals Expands R&D Operations with New Austin Facility
New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects Significantly...
Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically...
Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update
– Q2 2022 Consolidated Sales Growth of 8.3% to $19.3 million – Year-to-Date Revenue Growth of 13.9% or $37.8 million...
OraSure Technologies Launches New Product for Microbiome Researchers to Study DNA and RNA
BETHLEHEM, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home...
Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular...
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland,...
BUSINESS UPDATE
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Pipeline for future revenue generating partnered collaborations is strong with further deals...
Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial
As of the July 5, 2022, data cutoff, early CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths...
Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies
Confirmed safety profile at 300 mg/m2 or 1.5 times the therapeutic dose of docetaxel aloneConfirmed low levels of free docetaxel...
Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in...
Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and...
How AI Solves Pharma’s Data Disconnect
By Rohit Vashisht Competition in the pharmaceutical industry is driving a race to collect the most data and build the...